Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries LAWSUITS FILED AGAINST QFIN, ARDX and KPLT - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire September 10, 2021 at 14:55 PM EDT NEW YORK, NY / ACCESSWIRE / September 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.360 DigiTech, Inc. (NASDAQ:QFIN)CONTACT JAKUBOWITZ ABOUT QFIN:https://claimyourloss.com/securities/360-digitech-inc-loss-submission-form/?id=19493&from=1Class Period : April 29, 2021 - July 7, 2021Lead Plaintiff Deadline : September 13, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.Ardelyx, Inc. (NASDAQ:ARDX)CONTACT JAKUBOWITZ ABOUT ARDX:https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=19493&from=1Class Period : August 6, 2020 - July 19, 2021Lead Plaintiff Deadline : September 28, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Katapult Holdings, Inc. (NASDAQ:KPLT)CONTACT JAKUBOWITZ ABOUT KPLT:https://claimyourloss.com/securities/katapult-holdings-inc-loss-submission-form/?id=19493&from=1Class Period : December 18, 2020 - August 10, 2021Lead Plaintiff Deadline : October 26, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/663595/LAWSUITS-FILED-AGAINST-QFIN-ARDX-and-KPLT--Jakubowitz-Law-Pursues-Shareholders-Claims Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
LAWSUITS FILED AGAINST QFIN, ARDX and KPLT - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire September 10, 2021 at 14:55 PM EDT NEW YORK, NY / ACCESSWIRE / September 10, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.360 DigiTech, Inc. (NASDAQ:QFIN)CONTACT JAKUBOWITZ ABOUT QFIN:https://claimyourloss.com/securities/360-digitech-inc-loss-submission-form/?id=19493&from=1Class Period : April 29, 2021 - July 7, 2021Lead Plaintiff Deadline : September 13, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the Company had been collecting personal information in violation of relevant People's Republic of China laws and regulations; (ii) accordingly, 360 DigiTech was exposed to an increased risk of regulatory scrutiny and/or enforcement action; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.Ardelyx, Inc. (NASDAQ:ARDX)CONTACT JAKUBOWITZ ABOUT ARDX:https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=19493&from=1Class Period : August 6, 2020 - July 19, 2021Lead Plaintiff Deadline : September 28, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Katapult Holdings, Inc. (NASDAQ:KPLT)CONTACT JAKUBOWITZ ABOUT KPLT:https://claimyourloss.com/securities/katapult-holdings-inc-loss-submission-form/?id=19493&from=1Class Period : December 18, 2020 - August 10, 2021Lead Plaintiff Deadline : October 26, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Katapult was experiencing declining e-commerce retail sales and consumer spending, (2) despite Katapult's assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential goods and enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers' future buying behavior; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz Law View source version on accesswire.com: https://www.accesswire.com/663595/LAWSUITS-FILED-AGAINST-QFIN-ARDX-and-KPLT--Jakubowitz-Law-Pursues-Shareholders-Claims
